Qiagen stock gains 1.94 percent with Q2 results above estimates

Published on 09/25/2026 at 14:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock posted Q2 adjusted EPS of USD 0.62, 3.3 percent above consensus, in Q2 2026. Net sales reached USD 535 million, 1.4 percent above estimates, while 2026 guidance calls for 1-2 percent constant-currency growth.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0012169213) stood at USD 44.56 on the NYSE on September 24, 2026, up 1.94 percent from the prior close of USD 43.71. The move follows second-quarter 2026 results that exceeded consensus on both adjusted earnings and sales.

Q2 earnings top estimates

According to Zacks on September 4, 2026, Qiagen reported adjusted earnings per share of USD 0.62 for Q2 2026, 3.3 percent above consensus and 3.3 percent higher year over year. GAAP earnings per share reached USD 0.50, compared with USD 0.44 in the year-ago quarter.

Net sales came to USD 535 million, an increase of 0.3 percent from the prior-year quarter and 1.4 percent above consensus. Sample technologies generated USD 182 million, up 9 percent, while diagnostic solutions produced USD 204 million, down 1 percent on a reported basis.

Growth remains uneven

The operating mix explains why the earnings beat does not translate into a broader upgrade of expectations. PCR and nucleic acid amplification revenue fell 7 percent to USD 74 million, while genomics and next-generation sequencing revenue increased 3 percent to USD 61 million, according to Zacks.

Qiagen's adjusted operating margin was 29.4 percent in Q2 2026, 0.5 percentage points below the year-ago period. The company also generated USD 301 million in operating cash flow during the first half of 2026, giving the results a stronger cash profile than the flat overall sales growth suggests.

Analyst targets stay close

According to MarketBeat, JPMorgan raised its Qiagen target from USD 45.00 to USD 50.00 and assigned an overweight rating on August 7, 2026. The same overview lists an average analyst target of USD 43.51 and a consensus rating of Hold.

The market value of USD 9,190,500,000 on September 25, 2026, places the stock below the average target, while the 52-week range of USD 32.53 to USD 57.82 shows that the current quote remains well inside its annual trading band. Qiagen's investor-relations page identifies the company as listed on the NYSE under QGEN and on Xetra under QIA.

Qiagen stock stays above USD 44

Qiagen stock stood at USD 44.56 on the NYSE on September 24, 2026, at 4:00 p.m. ET. The daily change was 1.94 percent, with volume of 1,693,544 shares.